AncestryHealth
Also: NIH moves forward with physIQ's COVID digital biomarkers; Tyto Care adds pulse oximeter.
The consumer genomics company's existing offering, called AncestryHealth, sold clinician-ordered tests that were not cleared or approved by the FDA.
The deal is valued at roughly $4.7 billion.
The company said the product will give customers information about their genetic risk for certain diseases.
The Israel-based company is offering 11 genetic risk tests, three polygenic risk tests and 15 carrier status reports.